Merck and Institute for Systems Biology Enter COVID-19 Collaboration

Merck and the Institute for Systems Biology (ISB), have entered a new research collaboration to investigate and define the molecular mechanisms of SARS-CoV-2 infection and COVID-19 and identify targets for medicines and vaccines. Merck has also entered into an agreement with the Biomedical Advanced Research and Development Authority (BARDA), part of the office of the Assistant Secretary for Preparedness and Response within an agency of the U.S. Department of Health and Human Services, for BARDA to provide funding support for this research effort under Contract No. HHSO100201600031C. Findings generated from the study will be made available to the worldwide scientific and biomedical community.
 
“This collaboration with Merck provides critical support for the recently launched scientific trial being co-led by ISB and Swedish Medical Center, both part of the Providence St. Joseph Health network. We launched this trial with the urgent need to improve our understanding of COVID-19,” said Dr. Jim Heath, president, ISB. “By applying the full power of our systems biology capabilities, we hope to gain important insights into the molecular basis for the dramatically contrasting outcomes observed for patients infected with SARS-CoV-2.”
 
Through this collaboration, scientists from ISB, health workers from the Swedish Medical Center, and a consortium of research organizations and biomedical companies will analyze blood samples and nasal swabs from Swedish Medical Center patients with SARS-CoV-2 using samples from several time points (initial presentation, acute illness and convalescence). Blood samples will be examined using proteomic, metabolomic, transcriptomics and genetic techniques to evaluate the impact of infection on different organs, and to identify potential biomarkers to predict the risk of severe disease. In addition, samples will be analyzed to create a profile of the immune response, including quantitative changes in immune cells in patients following SARS CoV-2 infection and characterization of neutralizing antibodies in samples from convalescent patients. These insights can be used to inform vaccine design and antibody therapy. Under the agreement, Merck will provide research funding and work with researchers at ISB to characterize targets for potential therapeutic intervention and vaccine development. The study will initially analyze samples from 200 patients with the potential to expand to 300.
 
“Understanding the molecular characteristics of SARS-CoV-2 infection, and of the immune response to this virus, is essential to the development of effective interventions,” said Dr. Roger M. Perlmutter, president, Merck Research Laboratories. “We are eager to advance this work with ISB, and to share our findings with the broader scientific community. Interdicting the COVID-19 pandemic presents a daunting global health challenge, demanding unprecedented collaboration across the international scientific and medical communities to which we are proud to contribute.”